An independent Centers for Disease Control and Prevention advisory committee today recommended immediate resumption of the administration of Johnson & Johnson’s COVID-19 vaccine in the U.S. The vaccine maker would add a warning to its labeling materials about the risk of rare blood clots known as thrombosis with thrombocytopenia syndrome. The recommendation, which passed by a 10-4 vote with one abstention, now goes to the CDC for its approval. The Food and Drug Administration will amend Johnson & Johnson’s emergency use authorization to indicate that women under the age of 50 should be aware of the risk of blood clots from the vaccine.
CDC’s Clinician Outreach and Communication Activity will hold a Zoom call Tuesday, April 27 at 2 p.m. ET to discuss the latest evidence on thrombosis with thrombocytopenia syndrome after the administration of the Johnson & Johnson vaccine. Access the live webinar here, a recording of which will be available several hours after the live event ends.